Literature DB >> 24188571

Lung biopsy-proved hypersensitivity pneumonitis without known offending antigen: characteristics and follow-up.

Jin-Fu Xu1, Li Shen, Yuan Zhang, Peng Zhang, Jie-Ming Qu, Hui-Ping Li.   

Abstract

INTRODUCTION: Hypersensitivity pneumonitis (HP) without known offending antigen is hard to diagnose.
OBJECTIVES: The purpose of this study was to identify and analyze the clinical features of lung biopsy-proved HP.
METHODS: A retrospective cohort study was performed using a database from a 900-bed specialty hospital. Twenty-eight patients with the diagnosis of HP through lung biopsy were enrolled. Demographic data and clinical characteristics, radiologic characteristics, serologic and pulmonary function results, histopathologic changes, treatment and follow-up were analyzed.
RESULTS: Of all the patients, serum interleukin-1β, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), eosinophil cationic protein and immunoglobulin E (IgE) were increased in over 50% patients, but decreased significantly after corticosteroid therapy (P < 0.05). An initially reduced diffusion lung capacity for carbon monoxide was noted in 92.9% patients, while 39.3% patients had hypoxemia. Ground-glass opacities on the basis of interlobular septa thickening were observed in 71.4% cases. Histopathological findings demonstrated peribronchiolar lymphocytic infiltrates, poorly formed non-caseating granulomas fibrosis in all acute and subacute HP patients' lungs. Ninety-two percent of patients got improvement after corticosteroid therapy when assessed by computer tomography scans and pulmonary function tests.
CONCLUSIONS: For suspected HP patients who without known offending antigens, earlier diagnosed by lung biopsy and followed by corticosteroid therapy showed promising. It might prevent the disease progression to lung fibrosis.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  diagnosis; follow-up; hypersensitivity pneumonitis; lung biopsy; offending antigen

Mesh:

Substances:

Year:  2014        PMID: 24188571     DOI: 10.1111/crj.12071

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  1 in total

1.  Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.

Authors:  Violaine Giraud; Christine Longvert; Solène Houlle-Crepin; Claire Danel; Sylvie Labrune; Philippe Camus; Philippe Saiag; Thierry Chinet
Journal:  BMC Cancer       Date:  2015-10-19       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.